Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei
Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace
Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace
Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis. Source: BioSpace
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue…
Shire will have its new CFO in March. Source: BioSpace
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can't be treated with surgery. Source: BioSpace
Things are looking up for Massachusetts-based Homology Medicines. Source: BioSpace
CARMA Therapeutics is based on technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out of the laboratory of Saar Gill, assistant professor of…
The agency would have to furlough about 45 percent of its staff. Source: BioSpace
Investors and analysts have given it some thought and mostly think it's a sensible acquisition. Source: BioSpace
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers. Source: BioSpace